Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1993-09-14
2001-11-06
Kunz, Gary L. (Department: 1647)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S320100, C435S246000
Reexamination Certificate
active
06313276
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a human endothelin receptor, DNA sequence encoding the receptor, an expression vector carrying the DNA sequence, a transformant comprising the expression vector, and a method for producing a human endothelin receptor from the transformant.
2. Description of the Prior Art
An endothelin receptor (ET-receptor) is a receptor for an endothelin (ET). ET-receptors derived from animals such as bovines and rats have been known. An ET is a peptide present in various tissues in animals and is known as a strong vasoconstrictor. Cloning and sequence analysis of known ET genes have revealed that the ETs comprise three kinds of isopeptides: Endothelin 1 (ET-1), Endothelin 2 (ET-2), and Endothelin 3 (ET-3). Thereafter, it has been found that these ETs are distributed in a wide variety of vascular and non-vascular tissues (Proc. Natl. Acad. Sci. U.S.A. 86, 2863-2867 (1989); Trends in Pharmacol. Sci. 10, 374-378 (1989); and Proc. Natl. Acad. Sci. U.S.A. 87, 2359-2363 (1990)). ET-1 has initially been identified as a strong vasoconstrictive peptide with 21-amino-acid residues produced by porcine vascular endothelial cells (Nature, 332, 411-415 (1988)).
It has previously been shown in vivo that ET-1 and ET-2 are much more strong vasoconstrictors than ET-3, whereas the three ET isopeptides are roughly equipotent in producing the transient vasodilation.
As described above, the analysis of nucleic acid sequences of ETs has revealed that various kinds of ET isopeptides exist. These ET isopeptides are also different in their properties. Therefore, it appears that various subtypes of ET-receptors exist. The existence of various subtypes of ET-receptors has been proved by the radioactive ligand binding studies of Watanabe, H. et al. (Biochem. Biophys. Res. Commun., 161, 1252-1259 (1989)), and Martin, E. R. et al. (J. Biol. Chem. 265, 14044-14049 (1990)). These studies indicate the existence of, at least, two kinds of ET-receptors. One of them has a higher affinity for ET-1 and ET-2 than for ET-3; and the other has an affinity for ET-1, ET-2, and ET-3 with no selectivity.
The ET-receptor is useful as a reagent for measuring the amount of ET or useful in screening for an antagonist of the ET-receptor so as to study agents for the circulatory system. Therefore, there is a demand for a structure analysis of the ET-receptor and effective production of the ET-receptor by means of genetic engineering using the information of this structural analysis.
SUMMARY OF THE INVENTION
The human endothelin receptor of the present invention comprises amino acid sequence from Asp at +1 to Asn at +407 shown in SEQ ID NO:1 and SEQ. ID NO:2.
The human endothelin receptor of the present invention comprises amino acid sequence from Met at −20 to Asn at +407 shown in SEQ ID NO:1 and SEQ ID NO:2.
The DNA sequence of the present invention encodes the human endothelin receptor comprising amino acid sequence from Asp at +1 to Asn at +407 shown in SEQ ID NO:1 and SEQ ID NO:2.
The human endothelin receptor of the present invention comprises amino acid sequence from Glu at +27 to Ser at +442 shown in SEQ ID NO:3 and SEQ ID NO:4.
The human endothelin receptor of the present invention comprises amino acid sequence from Met at +1 to Ser at +442 shown in SEQ ID NO:3 and SEQ ID NO:4.
The DNA sequence of the present invention encodes the human endothelin receptor comprising amino acid sequence from Glu at +27 to Ser at +442 shown in SEQ ID NO:3 and SEQ ID NO:4.
The expression vector of the present invention comprises the DNA sequence encoding the human endothelin receptor having amino acid sequence from Asp at +1 to Asn at +407 shown in SEQ ID NO:1 and SEQ ID NO:2.
The transformant of the present invention is obtained by introducing into a host cell the expression vector comprising the DNA sequence encoding the human endothelin receptor having amino acid sequence from Asp at +1 to Asn at +407 shown in SEQ ID NO:1 and SEQ ID NO:2.
The expression vector of the present invention comprises the DNA sequence encoding the human endothelin receptor having amino acid sequence from Glu at +27 to Ser at +442 shown in SEQ ID NO:2.
The transformant of the present invention is obtained by introducing into a host cell the expression vector comprising the DNA sequence encoding the human endothelin receptor having amino acid sequence from Glu at +27 to Ser at +442 shown in SEQ ID NO:3 and SEQ ID NO:4.
The method for producing a human endothelin receptor of the present invention comprises culturing either one of the above-mentioned transformants and recovering a produced endothelin receptor.
Thus, the invention described herein makes possible the advantage of providing a human ET-receptor, DNA sequence encoding the ET-receptor, an expression vector carrying the DNA sequence, a transformant comprising the expression vector, and a method for producing an ET-receptor from the transformant.
REFERENCES:
patent: 0480381 (1992-04-01), None
Sakamoto et al., “Cloning and functional expression of human cDNA for ETB endothelin receptor”Chem. Abstracts(Jul. 6, 1992) 117(1):216.
Ogawa et al., “Molecular cloning of a non-isopeptide-selective human endothelin receptor”Chem. Abstracts(Mar. 30, 1992) 116(13):230.
Nakamuta et al., “Cloning and sequence analysis of a cDNA encoding human non-selective type of endothelin receptor”Chem. Abstracts(Mar. 30, 1992) 116(13):223.
Lin et al., “Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor”Chem. Abstracts(Mar. 2, 1992) 116(9):165.
Wada et al., Biochemical Biophysical Research Communications, vol. 167, pp. 251-257, 1990.*
Shimada et al., Eur. J. Pharmacology, v. 193, pp. 123, 1991.*
Hosoda et al., FEBS Letters, 287, 23, 1991.*
Adachi et al., Biochemical and Biophysical Res. Communications, 180, 1265, 1991.*
Yanagisawa et al.,Trends in Pharmacol. Sci.(1989) 10:374-378.
MacCumber et al.,Proc. Natl. Acad. Sci.(1990) 87:2359-2363.
Yanagisawa et al.,Nature(1988) 332:411-415.
Watanabe et al.,Biochem. Biophys. Res. Commun.(1989) 161(3):1252-1259.
Martin et al.,J. Biol. Chem.(1990) 265(23):14044-14049.
Sakurai et al.,Nature(1990) 348:732-735.
Adachi et al., “Cloning and characterization of cDNA encoding human A-type endothelial receptor”Biochem. Biophys. Res. Comm.(1991) 180(3):1265-1272.
Cyr et al., “Cloning and chromosomal localization of a human endothelial ETA receptor”Biochem. Biophys. Res. Comm.(1991) 181(1):184-190.
Hosoda et al., “Cloning and expression of human endothelial-1 receptor cDNA”FEBS Letters(1991) 287(1,2):23-26.
Nakamuta et al., “Cloning and sequence analysis of a cDNA clone encoding human non-selective type of endothelin receptor”Biochem. Biophys. Res. Comm.(1991) 177(1):34-39.
Ogawa et al., “Molecular cloning of a non-isopeptide-selective human endothelin receptor”Biochem. Biophys. Res. Comm.(1991) 178(1):248-255.
Sakamoto et al., “Cloning and functional expression of human cDNA for the ETBendothelin receptor”Biochem. Biophys. Res. Comm.(1991) 178(2):656-663.
Arai et al., 1990, Nature, 348, 730.*
Lin et al., 1991, PNAS, 88, 3185.*
Masuda et al., 1989, FEB, 257, 208.*
Kloog et al., 1989, FEB, 253, 199.*
Inoue et al., 1989, PNAS, 86, 2863.*
Masu et al., 1987, Nature, 329, 836.
Imura Hiroo
Nakanishi Shigetada
Nakao Kazuwa
Kunz Gary L.
Morrison & Foerster / LLP
Shionogi Sieyaku Kabushiki Kaisha
LandOfFree
Human endothelin receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human endothelin receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human endothelin receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2612095